

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				INT'L FILING NO.			
				INT'L FILING DATE			
				APPLICANT			
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60626USw	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	4,210,749	7/1/1980	Shetty			
	2.	5,364,791	11/15/1994	Vegeto et al.			
	3.	5,874,534	2/23/1999	Vegeto et al.			
	4.	5,935,934	10/10/1999	Vegeto et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	5.	WO 96/05194	2/2/1996	PCT			abstract only
	6.	WO 00/23437	4/27/2000	PCT			abstract only
	7.	WO 02/02530	1/10/2002	PCT			abstract only
	8.	WO 01/03680	1/18/2001	PCT			
	9.	WO 01/87834	11/22/2001	PCT			
	10.	WO 02/14513	2/21/2002	PCT			abstract only
	11.	WO 00/21951	4/20/2000	PCT			
	12.	WO 02/15934	2/28/2002	PCT			abstract only
	13.	WO 02/46186	6/13/2002	PCT			abstract only
	14.	WO 03/68751	8/21/2003	PCT			
	15.	WO 03/68752	8/21/2003	PCT			
	16.	WO 03/95428	11/20/2003	PCT			
	17.	WO 04/56369	7/8/2004	PCT			
	18.	1 331 010	7/30/2003	EP			
	19.	2207430	7/23/1981	DE			abstract only
	20.	2171879	9/28/1973	FR			abstract only
	21.	1 268 243	3/22/1972	GB			
	22.	2001226269	8/21/2001	JP			abstract only
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	23.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," <i>Behavioural Brain Res.</i> <b>104</b> :147-155 (1999).					
	24.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," <i>TiPS</i> <b>19</b> :177-183 (May 1998).					
	25.	LOVENBERG et al., "Cloning and Functional Expression of the Human Histamine H <sub>3</sub> Receptor," <i>Molecular Pharmacology</i> <b>55</b> :1101-1107 (1999).					
	26.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).					
	27.	SCHLICKER et al., "Modulation of neurotransmitter release <i>via</i> histamine H <sub>3</sub> heteroreceptors," <i>Fundam Clin Pharmacol</i> <b>8</b> :128-137 (1994).					
	28.	STARK, Recent advances in histamine H <sub>3</sub> /H <sub>4</sub> receptor ligands, <i>Expert Opinion on Therapeutic Patents</i> <b>13(6)</b> :851-865 (2003).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							